How to Choose the Best First-Line Therapy for Patients With EGFR-Mutated NSCLC
How to Choose the Best First-Line Therapy for Patients With EGFR-Mutated NSCLC

Susan Scott, MD, Estelamari Rodriguez, MD, MPH, Helena Yu, MD

New Insights From the MARIPOSA Trial: Amivantamab Plus Lazertinib for EGFR-Mutated NSCLC
New Insights From the MARIPOSA Trial: Amivantamab Plus Lazertinib for EGFR-Mutated NSCLC

Helena Yu, MD, Joshua Sabari, MD

Targeted Therapies in EGFR-Mutated NSCLC: Managing Treatment-Related AEs
Targeted Therapies in EGFR-Mutated NSCLC: Managing Treatment-Related AEs

Estelamari Rodriguez, MD, MPH, Helena Yu, MD, Joshua Sabari, MD